Clinical trials: Metastasis to Brain of Primary Cancer
Breast Cancer, Brain Metastases
A Phase II Study of T-DXd Plus SRT in HER2-positive Breast Cancer Brain Metastases
This research study will evaluate the efficacy and safety of stereotactic radiotherapy (SRT) combined with Trastuzumab-Deruxtecan (T-DXd; DS-8201a) in HER2-positive Breast Cancer Patients with newly diagnosed or progressing Brain…
- Conditions
- Breast Cancer, Brain Metastases, Radiotherapy
- Trial name
- NCT06088056
- Testing
- Combination use of SRT with T-DXd
- Where
- China
- Volunteers
- 17 people
- Sponsor
- Fudan University
Brain and Central Nervous System Tumors
Cytochlor, Tetrahydrouridine, and External-Beam Radiation Therapy in Treating Patients With Cancer That Has Spread to the Brain
RATIONALE: Radiation therapy uses high-energy x-rays to kill tumor cells. Drugs, such as cytochlor and tetrahydrouridine, may make tumor cells more sensitive to radiation therapy.
- Trial name
- NCT00521183
- Testing
- Cytochlor, Tetrahydrouridine, Radiation Therapy
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- Brian Lally
Metastatic Breast Cancer
A Phase 1b/2 Study of T-DXd Combinations in HER2-positive Metastatic Breast Cancer
DESTINY-Breast07 will investigate the safety, tolerability, and anti-tumour activity of trastuzumab deruxtecan (T-DXd) in combination with other anti-cancer agents in patients with HER2-positive Metastatic Breast Cancer
- Trial name
- DB-07 (NCT04538742)
- Testing
- Trastuzumab deruxtecan, Durvalumab, Paclitaxel
- Where
- 72 sites in United States, Australia and 13 more
- Volunteers
- 245 people
- Sponsor
- AstraZeneca
Neoplasms, Breast
Lapatinib for Brain Metastases In ErbB2-Positive Breast Cancer
Determine how safe and effective lapatinib is when used to treat patients with ErbB2 overexpressing breast cancer that has spread to the brain and is still progressing there even after radiation treatment using WBRT (whole brain…
- Trial name
- NCT00263588
- Testing
- lapatinib
- Where
- 74 sites in United States, Australia and 15 more
- Volunteers
- 242 people
- Sponsor
- Novartis Pharmaceuticals
Central Nervous System (CNS) Lesions, Brain Metastases
Phase 2 Ascending Dose Safety and Efficacy Study of RVP-001, a Manganese-based MRI Contrast Agent
This Phase 2 clinical trial will study RVP-001, a new manganese-based MRI contrast agent, in people who are known to have gadolinium-enhancing central nervous system (CNS) lesions, for example brain tumors or multiple sclerosis.
- Conditions
- Central Nervous System (CNS) Lesions, Brain Metastases, Brain Neoplasms, Brain Neoplasms, Benign
- Trial name
- NCT06322342
- Testing
- RVP-001
- Where
- 5 sites in United States
- Volunteers
- 18 people
- Sponsor
- Reveal Pharmaceuticals Inc.
Extensive Stage Lung Small Cell Carcinoma, Malignant Solid Neoplasm
Testing the Addition of an Anti-cancer Drug, Entinostat, to the Usual Chemotherapy and Immunotherapy Treatment (Atezolizumab, Carboplatin and Etoposide) for Previously Untreated Aggressive Lung Cancer That Has Spread
This phase I trial seeks to find out the best dose, possible benefits and/or side effects of entinostat in combination with atezolizumab, carboplatin and etoposide for the treatment of previously untreated aggressive lung cancer…
- Conditions
- Extensive Stage Lung Small Cell Carcinoma, Malignant Solid Neoplasm, Metastatic Malignant Neoplasm in the Brain
- Trial name
- NCT04631029
- Testing
- Atezolizumab, Carboplatin, Entinostat
- Where
- 5 sites in United States
- Volunteers
- 3 people
- Sponsor
- National Cancer Institute (NCI)
Brain Metastases, Non Small Cell Lung Cancer
Sintilimab Combined With Bevacizumab for Brain Metastases From Non-small Cell Lung Cancer
This is a prospective phase II clinical study to assess the efficacy of Sintilimab combined with Bevacizumab for driving gene-negative, asymptomatic brain metastases from non-small cell lung cancer by intracranial ORR(iORR),also…
- Conditions
- Brain Metastases, Non Small Cell Lung Cancer, Sintilimab, Bevacizumab
- Trial name
- NCT04213170
- Testing
- sintilimab
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Sun Yat-sen University
Brain Metastases, Non-small Cell Lung Cancer
Hippocampus-Avoidance Whole-Brain Radiation Therapy With Simultaneous Integrated Boost for BMs of NSCLC
WBRT (whole-brain radiation therapy) exhibits poor tumor control and decreased NCF (neurocognitive function). Herein, we investigated the safety and efficacy of HA-WBRT+SIB (hippocampus-avoidance whole-brain radiation therapy…
- Trial name
- NCT06557187
- Testing
- ippocampus-Avoidance Whole-Brain Radiation Therapy With Simultaneous Integrated Boost
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Yatian Liu
Long-term Effects Secondary to Cancer Therapy in Children, Neurotoxicity
Brain Function in Children Previously Treated on Clinical Trials POG-9605 and POG-9201
RATIONALE: Assessing the effects of methotrexate on brain function in children may improve the ability to plan treatment and decrease side effects.
- Trial name
- NCT00028509
- Testing
- management of therapy complications
- Where
- 26 sites in United States, Canada
- Volunteers
- 66 people
- Sponsor
- Children's Oncology Group
Lung Cancer
Prophylactic Cranial Irradiation in Patients With Lung Adenocarcinoma With High Risk of Brain Metastasis
Lung cancer is the first cause of death among cancer patients. Non Small Cell lung cancer (NSCLS) represents about 80-85% of the cases. Of this, about 80% presents with locally advanced or metastatic disease.
- Trial name
- PCI (NCT01603849)
- Testing
- Prophylactic Cranial Irradiation
- Where
- Mexico
- Volunteers
- 84 people
- Sponsor
- Instituto Nacional de Cancerologia de Mexico
Brain Metastases, Bone Metastases
Dual Energy CT - a Tool for Delineation of Tumor and Organs at Risk in Radiotherapy
The primary aim of this clinical study, 'Dual Energy CT - a tool for delineation of tumor and organs at risk in radiotherapy' (DART) is to evaluate whether dual-energy CT (DECT) is at least as effective as magnetic resonance…
- Conditions
- Brain Metastases, Bone Metastases, Head and Neck Cancer, Lung Cancer
- Trial name
- DART (NCT07185958)
- Testing
- Dual-energy CT (DECT), Iodine-based contrast agent, Magnetic Resonance Imaging (MRI)
- Where
- 3 sites in Denmark
- Volunteers
- 80 people
- Sponsor
- Aalborg University Hospital
Lung Cancer, Metastatic Cancer
Whole-Brain Radiation Therapy and Pemetrexed in Treating Patients With Brain Metastases From Non-Small Cell Lung Cancer
RATIONALE: Radiation therapy uses high-energy x-rays to kill tumor cells. Pemetrexed may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
- Trial name
- NRR (NCT00280748)
- Testing
- pemetrexed disodium, radiation therapy
- Where
- 2 sites in United States
- Volunteers
- 10 people
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
Non Small Cell Lung Cancer, Brain Metastases
Cadonilimab Combined With Stereotactic Radiotherapy as Second-line Treatment for Brain Metastases
The goal of this clinical trial is to evaluate the efficacy and safety of Cadonilimab combined with stereotactic radiation therapy in the second-line treatment of brain metastases from non-small cell lung cancer (NSCLC).
- Conditions
- Non Small Cell Lung Cancer, Brain Metastases, Stereotactic Radiation, Immunotherapy
- Trial name
- NCT06702826
- Testing
- Cadonilimab combined with SRS
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Rongrong Zhou
Brain Metastases, Small Cell Lung Cancer
Hair-sparing Whole Brain Radiotherapy
Up to 10% of patients with cancer will develop symptomatic brain metastases. Given this limited survival it is important to consider quality of life (QOL) when treating these patients.
- Trial name
- NCT01421316
- Testing
- Whole brain radiotherapy with volumetric arc therapy
- Where
- Belgium
- Volunteers
- 29 people
- Sponsor
- University Hospital, Ghent
Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Malignant Neoplasm in the Brain
Dendritic Cell Vaccines Against Her2/Her3 and Pembrolizumab for the Treatment of Brain Metastasis From Triple Negative Breast Cancer or HER2+ Breast Cancer
This phase IIa trial studies how well dendritic cell vaccines against Her2/Her3 and pembrolizumab work for the treatment of triple negative breast cancer or HER2+ breast cancer or HER+ Breast cancer that has spread to the brain…
- Conditions
- Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Malignant Neoplasm in the Brain, Metastatic Triple-Negative Breast Carcinoma, Prognostic Stage IV Breast Cancer AJCC v8
- Trial name
- NCT04348747
- Testing
- Anti-HER2/HER3 Dendritic Cell Vaccine, Pembrolizumab
- Where
- 3 sites in United States
- Volunteers
- 23 people
- Sponsor
- Roswell Park Cancer Institute
Breast Cancer, Brain Metastasis
PCI in Advanced Triple Negative Breast Cancer Patients Who Response to 1st Line Chemotherapy
The purpose of this study is to compare whether prophylactic cranial irradiation in patients with advanced triple negative breast cancer who had a response to first line chemotherapy could prolong brain-metastasis free survival.
- Trial name
- NCT02448576
- Testing
- prophylactic cranial irradiation
- Where
- China
- Volunteers
- 326 people
- Sponsor
- wang shusen
Nonsmall Cell Lung Cancer
Chemotherapy With or Without Radiosurgery for Asymptomatic Oligo Brain Metastasis
The need of radiosurgery is controversial for asymptomatic oligo brain metastasis for non small cell lung cancer (NSCLC). Therefore, the investigators do a randomized study comparing overall survival between two groups with or…
- Trial name
- NCT01301560
- Testing
- Radiosurgery, Observation
- Where
- South Korea
- Volunteers
- 176 people
- Sponsor
- Samsung Medical Center
Breast Cancer, Estrogen Receptor-Positive
Validity of Brain Metastasis Risk Predictive Model in Hormone Positive Breast Cancer Patients
This study aims to validate a prediction model of brain metastasis risk for females with HR+ breast cancer by using variables collected at diagnosis.
- Trial name
- NCT06729099
- Volunteers
- 128 people
- Sponsor
- Assiut University
Non Small Cell Lung Cancer Metastatic
A Study of Stereotactic Radiosurgery (SRS) and Standard Treatment in People With Lung Cancer That Has Spread to the Brain
The researchers are doing this study is to find out whether treating brain metastasis with SRS after 3 months of therapy with osimertinib is better than treating with osimertinib alone in people with NSCLC.
- Trial name
- NCT06741085
- Testing
- osimertinib, stereotactic radiosurgery (SRS)
- Where
- 8 sites in United States
- Volunteers
- 56 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Breast Cancer, HER2-positive Breast Cancer
Trastuzumab Deruxtecan + Stereotactic Radiosurgery (SRS) in HER2+ Breast Cancer Brain Metastases
A phase I clinical trial (a type of research study) for people with human epidermal growth factor receptor 2 (HER-2) positive breast cancer with metastasis to the brain.
- Conditions
- Breast Cancer, HER2-positive Breast Cancer, Brain Metastases, Cancer
- Trial name
- NCT07454668
- Testing
- Trastuzumab Deruxtecan, Stereotactic Radiosurgery
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Baptist Health South Florida